Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +207.46%
#3 ONFA ONFA +54.25%
#4 Metaplex Metaplex +23.40%
#5 Osaka Protocol Osaka Protocol +21.73%
#6 Talus Network Talus Network +20.44%
#7 Wrapped Krown Wrapped Krown +20.00%
#8 DODO DODO +17.78%
#9 Black Phoenix Black Phoenix +15.04%
#10 eCash eCash +13.30%
Coin of the day
DeFiChain DeFiChain
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rang in aandelen #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Aandeelprijs
$0.94180721
Marktkapitalisatie
$22.26M
Verandering (1 dag)
0.38%
Verandering (1 jaar)
-14.35%
Land
FR
Handel Valbiotis SA (ALVAL)

Categorie

Healthcare
P/B-ratio voor Valbiotis SA (ALVAL)
P/B-ratio op July 2026 TTM: 2.69
Volgens de meest recente financiële rapporten en aandelenkoers van Valbiotis SA is de huidige P/B-ratio (TTM) 2.69. Eind 2023 had het bedrijf een P/B-ratio van 3.18.
P/B-ratiohistoriek voor Valbiotis SA van 2015 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
2026 (TTM) 2.69 16.05%
2024 2.32 -27.16%
2023 3.18 16.23%
2022 2.74 -37.95%
2021 4.41 -30.21%
2020 6.32 392.65%
2019 1.28 -22.00%
2018 1.64 -0.78%
2017 1.66 -98.28%
2016 96.41 6,215.43%
2015 1.53 0.00%
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 6.9942 159.78%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.251 132.17%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.1715 -19.35%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.065 50.98%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3009 171.17%
NL